Cyclo Therapeutics Stock Fundamentals
| CYTH Stock | USD 0.64 0.08 11.11% |
Cyclo Therapeutics fundamentals help investors to digest information that contributes to Cyclo Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyclo Stock. The fundamental analysis module provides a way to measure Cyclo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclo Therapeutics stock.
As of now, Cyclo Therapeutics' Total Operating Expenses is increasing as compared to previous years. The Cyclo Therapeutics' current Selling And Marketing Expenses is estimated to increase to 7,002, while Depreciation And Amortization is projected to decrease to under 18.3 K. Cyclo | Select Account or Indicator |
Cyclo Therapeutics Company Current Valuation Analysis
Cyclo Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cyclo Therapeutics Current Valuation | 29.76 M |
Most of Cyclo Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyclo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cyclo Therapeutics has a Current Valuation of 29.76 M. This is 99.79% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 99.82% higher than that of the company.
Cyclo Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cyclo Therapeutics's current stock value. Our valuation model uses many indicators to compare Cyclo Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cyclo Therapeutics competition to find correlations between indicators driving Cyclo Therapeutics's intrinsic value. More Info.Cyclo Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . As of now, Cyclo Therapeutics' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclo Therapeutics' earnings, one of the primary drivers of an investment's value.Cyclo Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclo Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclo Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclo Therapeutics by comparing valuation metrics of similar companies.Cyclo Therapeutics is currently under evaluation in current valuation category among its peers.
Cyclo Fundamentals
| Return On Equity | -226.64 | ||||
| Return On Asset | -2.82 | ||||
| Operating Margin | (45.78) % | ||||
| Current Valuation | 29.76 M | ||||
| Shares Outstanding | 28.77 M | ||||
| Shares Owned By Insiders | 40.07 % | ||||
| Shares Owned By Institutions | 13.17 % | ||||
| Number Of Shares Shorted | 131.61 K | ||||
| Price To Book | 59.10 X | ||||
| Price To Sales | 18.29 X | ||||
| Revenue | 1.08 M | ||||
| Gross Profit | 1.23 M | ||||
| EBITDA | (20.03 M) | ||||
| Net Income | (20.06 M) | ||||
| Cash And Equivalents | 4.29 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 1.03 M | ||||
| Current Ratio | 2.93 X | ||||
| Book Value Per Share | 0.17 X | ||||
| Cash Flow From Operations | (16.19 M) | ||||
| Short Ratio | 3.82 X | ||||
| Earnings Per Share | (0.90) X | ||||
| Target Price | 0.95 | ||||
| Beta | -0.38 | ||||
| Market Capitalization | 20.71 M | ||||
| Total Asset | 13.25 M | ||||
| Retained Earnings | (83.86 M) | ||||
| Working Capital | 3.85 M | ||||
| Net Asset | 13.25 M |
About Cyclo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -3.3 M | -3.1 M | |
| Total Revenue | 1.1 M | 995.2 K | |
| Cost Of Revenue | 3.5 M | 3.7 M | |
| Stock Based Compensation To Revenue | 0.68 | 0.72 | |
| Sales General And Administrative To Revenue | 5.26 | 5.52 | |
| Research And Ddevelopement To Revenue | 13.18 | 13.83 | |
| Revenue Per Share | 0.07 | 0.06 | |
| Ebit Per Revenue | (18.63) | (17.70) |
Currently Active Assets on Macroaxis
When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:Check out Cyclo Therapeutics Piotroski F Score and Cyclo Therapeutics Altman Z Score analysis. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.